Over the last year, Eli Lilly’s stock is up a very respectable 25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster -21%. Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for its new weight-loss drug C...
Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria's heavily-patented DehydraTECH drug delivery technology might improve bioavailability, lower costs, and enhance tolerability, weight-loss po...
fell short of the 25% weight loss that Novo Nordisk projected previously for its next-generation drug. The company has predicted CagriSema will help patients lose “at least 25%” of their body weight. That would make it the most effective treatment yet, in terms of pounds lost in a large...
That trial is crucial because Novo Nordisk is waiting to see that data before filing for approval of the oral weight loss drug, said Cowen's Nedelcovych. He added that in the long term, the availability of weight-loss pills could boost capacity for their injectable counterparts. Also in 202...
Novo Nordisk Stocks Plummet Over 20% on Disappointing Weight-Loss Drug Trial Results TMTPOST -- Novo Nordisk A/S shares plummeted as much as 27%, wiping up to $125 billion off in the market value, and settled 20.8% lower on Friday. Shares registered their worst day since listing in ...
The drug will also be available privately, but the manufacturer has not disclosed how much this will cost. In the US, the drug sells for as much as $1,350 (£1,070) a month. The NHS has also been urged to use virtual platforms to prescribe weight loss drugs in fu...
He also sees GLP-1 drugmakers following a similar trajectory to AI-linked stocks. "It's a little bit like thinking aboutNvidiawith AI. They just have a head start," Mazza said. "[Eli Lilly and Novo Nordisk] pivoted to focus on diabetes and weight ...
As aport strike stretching from New England to Texashalted nearly half of all trade coming into the U.S., customs data shows that critical medical devices and drug components for thebooming, expensive weight-loss and diabetes drugsfrom Novo Nordisk and Eli Lilly — Ozempic, Wegovy, Mounjaro ...
Amgen Raises Expectations for Weight-Loss Drug Discussinginterim datafrom a Phase 2 trial of the company’s weight-loss drug, Amgen CEO Robert Bradway said “we are very encouraged with results that we’ve seen thus far.” The firm did not release any of the results. ...
When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years